Latest news and press releases about Rallybio Corporation (RLYB): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Rallybio Corporation is a clinical-stage biotechnology firm dedicated to discovering and bringing to market transformative therapies for individuals facing severe and uncommon illnesses. Its most advanced therapeutic candidate, RLYB212, is a monoclonal anti-HPA-1a antibody currently undergoing Phase II clinical trials. This candidate, along with RLYB211, is aimed at preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT).
Price
| Price | $17.09 |
| Market Cap | $91M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 2.14 |
| Price / Book | 1.02 |
| EV / EBITDA | -0.11 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 68.56% |
| Return on Invested Capital | -24.40% |
| Return on Assets | 46.45% |
| Gross Margin | -1107.59% |
| Operating Margin | -3672.29% |
| Net Margin | 7051.24% |
Related companies: BOLD · CVKD · IBIO · INTS · ITRM · KLTO · QTTB
Explore sector: Healthcare · Biotechnology
More sections of RLYB: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks